spacer
home > ebr > spring 2002 > canada - the number one country for conducting biomedical r&d
PUBLICATIONS
European Biopharmaceutical Review

Canada - The Number One Country for Conducting Biomedical R&D

While lower cost is a compelling reason for conducting R&D in Canada, it is just one of several. Other factors include:

Canada is home to one of the largest, most developed biotech sectors in the world

The potential for partnerships with biotech firms undertaking cutting edge R&D exists throughout Canada

Government funding and tax credits for R&D is generous

Regulations are science-based and conducive to commercialising new products

Social and demographic features make Canada an excellent place to conduct clinical trials

Market-size is enormous, since Canada as a member of the North American Free Trade Agreement (NAFTA) has increased access to both the US and Mexican marketplace


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Michael Rappaport, Publications Supervisor at BIOTECanada Michael Rappaport is the Editor of BIOTECanada Insights, a bilingual, biannual magazine designed to promote the Canadian biotech sector, and BIOTECanada Monthly Reporter, an industry newsletter that provides updates on government relations activities and communications initiatives. Before assuming the position of Publications Supervisor at BIOTECanada, Michael was a Science Writer for the Natural Science and Engineering Research Council, the main funding body for biological, chemical, physical and engineering sciences in Canada. He has a BA Honours degree in English Literature and Political Science, and a Master of Journalism from Carleton University in Ottawa.
spacer
Michael Rappaport
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Introduces New Integrated Plug & Play Upstream Development Service

Adaptive approach to cell line development, analytics and clone selection for emerging biotechs and start-up Tailored upstream development from a single source reduces time to clinic by 20 percent Fast-track process reduces timeline by 10 weeks for first pharmacodynamic experiment
More info >>

White Papers

Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands

West Pharmaceutical Services, Inc.

The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement